Medical application of przewaquinone A

A technology of purple salvia and A, which is used in pharmaceutical formulations, medical preparations containing active ingredients, antitumor drugs, etc.

Inactive Publication Date: 2013-03-13
KUNMING UNIV OF SCI & TECH
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Salvia miltiorrhiza is a diterpene quinone compound isolated from Salvia ganxie. Through literature review, it was found that this compound has pharmacological activities of anti-oxidation and inhibition of vasoconstriction. There is no report that this compound can be used as an angiogenesis inhibitor and anticancer drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of przewaquinone A
  • Medical application of przewaquinone A
  • Medical application of przewaquinone A

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Embodiment 1: Preparation of purple danshenin (the purple danshenin used in the following examples is prepared by the following method)

[0020] In the experiment, 7.3 kg of dried sage (whole herb) was used, crushed through a 60-mesh sieve, ultrasonically extracted 5 times with 100% acetone (20 L each time) at room temperature, and the extract was concentrated under reduced pressure to obtain 300 g of crude extract; Put the obtained crude extract on a normal-phase silica gel column (80-100 mesh, Qingdao Ocean Chemical) (dry loading), and sequentially use pure petroleum ether, petroleum ether-ethyl acetate mixture (petroleum ether: ethyl acetate (9:1, 3:1, 1:1, 3:7) were eluted, and each part of the eluate was collected, concentrated under reduced pressure, and the concentrated solution was separately transferred to a 10mL penicillin bottle, and detected by TLC, the components were roughly the same The cuts of petroleum ether: ethyl acetate=1:1 eluent elution part (52 g)...

Embodiment 2

[0024] Example 2: Effect of Danshen A on the proliferation of human liver cancer cell line HepG-2 (MTT)

[0025] The human liver cancer cell line HepG-2 was incubated at 37°C in 5% CO 2 After culturing under the above conditions for 24 hours, inoculate them into a 96-well plate at a density of 3000 cells per well. , 10.0 mg / L of different concentrations of liquid medicine, and added to a 96-well plate, at 37 ℃, 5% CO 2 The culture was continued for 72 hours under the condition of 2, 20 μL of MTT (3-(4,5-dimethylthiazole-2)-2,5-diphenyltetrazolium bromide) was added to each well and the incubation was continued for 4 h, and the upper To the supernatant, 150 μL DMSO was added to each well, shaken for 1 h, and the absorbance OD value was measured at 490 nm on a microplate reader. (See figure 2 )

[0026] Experimental results such as image 3 It was shown that when the concentration of salvianolin A was greater than 2.5 mg / L, the proliferation activity of cells decreased si...

Embodiment 3

[0027] Example 3: Experiment of the inhibitory effect of purple danshen A on angiogenesis of chicken embryo allantoic membrane

[0028] Take fresh eggs at a temperature of 37.8 °C, CO 2The concentration was 5%, and the humidity was suitable for incubation for 7 days. A window (1×1 cm) was opened at the end of the air chamber, and a sterile filter paper sheet with a diameter of 6 mm was used as the drug delivery carrier, which was placed on the allantoic membrane. Administration groups with different concentrations of 5.0, 10.0, and 15.0 mg / L were administered, and a blank group (normal saline group) and a positive control drug group (dexamethasone group) were set up, and the window was sealed with scotch tape, and incubation was continued under the above conditions. After 48 hours, the allantoic membrane tissue was removed, put into dehydration solution (methanol:acetone=1:1) for dehydration and fixed for 15 min, and the blood vessels on the surface of the allantoic membrane t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of przewaquinone A, namely a diterpenoid quinine compound, in preparation of a medicament for resisting tumor vessel angiogenesis. According to the invention, the przewaquinone A is taken as an angiogenesis inhibitor and a malignant tumor resisting reagent, wherein the angiogenesis inhibitor can be used for inhibiting proliferation and diffusion of malignant cells by inhibiting angiogenesis in malignant tissues. Experiments prove that the przewaquinone A can be used for effectively inhibiting the proliferation of the malignant cells and has an obvious inhibition effect on the abnormal growth of the vessels, and therefore the przewaquinone A can be used for preparing the medicament for resisting the tumor vessel angiogenesis.

Description

technical field [0001] The invention belongs to the field of herbal medicinal components and anti-angiogenesis compounds, and in particular relates to the use of salvia salviae in the preparation of anti-tumor angiogenesis drugs. Background technique [0002] Angiogenesis is an important physiological and pathological process in the body. Angiogenesis refers to the process of sprouting new blood vessels from existing blood vessels. During embryonic development, angiogenesis has always been carried out. When individual development is completed, except for normal physiological processes such as wound healing and female menstruation, angiogenesis will not occur in adults. Studies in recent years have shown that the abnormal formation of new blood vessels in the body may be the root cause of serious diseases such as cancer, rheumatoid arthritis, diabetic blindness, and systemic lupus erythematosus. [0003] Cancer has been recognized as the number one disease that threatens hum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/58A61P35/00
Inventor 李宝才朱路平庄文婷李鹏向诚何静秦谊戴伟锋张敉
Owner KUNMING UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products